留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

耐受性树突状细胞的研究进展

徐海燕 何小舟

徐海燕, 何小舟. 耐受性树突状细胞的研究进展[J]. 器官移植, 2014, 5(1): 49-53. doi: 10.3969/j.issn.1674-7445.2014.01.013
引用本文: 徐海燕, 何小舟. 耐受性树突状细胞的研究进展[J]. 器官移植, 2014, 5(1): 49-53. doi: 10.3969/j.issn.1674-7445.2014.01.013

耐受性树突状细胞的研究进展

doi: 10.3969/j.issn.1674-7445.2014.01.013
基金项目: 

江苏省常州市卫生局重大课题 ZD201111

详细信息
    通讯作者:

    何小舟,Email:hxz911@sina.com

  • 中图分类号: R617

  • [1] Steptoe RJ,Thomson AW. Dendritic cells and tolerance induction[J]. Clin Exp Immunol,1996,105(3):397-402. doi: 10.1046/j.1365-2249.1996.d01-779.x
    [2] Coquerelle C, Moser M. DC subsets in positive and negative regulation of immunity[J]. Immunol Rev,2010,234(1):317-334. doi: 10.1111/imr.2010.234.issue-1
    [3] Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation[J]. Semin Immunol,2011,23(4):252-263. doi: 10.1016/j.smim.2011.06.007
    [4] Fischer RT, Turnquist HR, Wang Z, et al. Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8(+) T cells in vitro and in vivo[J]. Transpl Immunol,2011,25(1):20-26. doi: 10.1016/j.trim.2011.05.001
    [5] Naranjo-Gómez M, Raïch-Regué D, Oñate C, et al. Comparative study of clinical grade human tolerogenic dendritic cells[J]. J Transl Med,2011,9:89. doi: 10.1186/1479-5876-9-89
    [6] Chamorro S, García-Vallejo JJ, Unger WW, et al. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program[J]. J Immunol,2009,183(5):2984-2994. doi: 10.4049/jimmunol.0801155
    [7] 李永海,张淦,李明,等.NOD小鼠未成熟树突状细胞体外诱导淋巴细胞生成并扩增调节性T细胞的研究[J].器官移植,2011,2(3):129-134. http://www.organtranspl.com/browse/detail/qkid/52/id/488.html

    Li YH, Zhang G,Li M, et al. Research on induction and expansion of regulatory T cells by immature dendritic cells of NOD mice in vitro[J]. Organ Transplant,2011,2(3):129-134. http://www.organtranspl.com/browse/detail/qkid/52/id/488.html
    [8] Nikolic T, Roep BO. Regulatory multitasking of tolerogenic dendritic cells-lessons taken from vitamin D3-treated tolerogenic dendritic cells[J]. Front Immunol,2013,4:113. http://cn.bing.com/academic/profile?id=2013395898&encoded=0&v=paper_preview&mkt=zh-cn
    [9] Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T cells[J]. Cell Biosci,2011,1(1):20. doi: 10.1186/2045-3701-1-20
    [10] Thomson AW, Turnquist HR, Zahorchak AF, et al. Tolerogenic dendritic cell-regulatory T-cell interaction and the promotion of transplant tolerance[J]. Transplantation,2009,87(9 Suppl):S86-S90. http://cn.bing.com/academic/profile?id=1988202577&encoded=0&v=paper_preview&mkt=zh-cn
    [11] Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells[J]. Blood,2011,118(20):5498-5505. doi: 10.1182/blood-2011-07-365825
    [12] Takayama T, Nishioka Y, Lu L, et al. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness[J]. Transplantation,1998,66(12):1567-1574. doi: 10.1097/00007890-199812270-00001
    [13] Min WP, Gorczynski R, Huang XY, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival[J]. J Immunol,2000,164(1):161-167. doi: 10.4049/jimmunol.164.1.161
    [14] Bonham CA, Peng L, Liang X, et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig[J]. J Immunol,2002,169(6):3382-3391. doi: 10.4049/jimmunol.169.6.3382
    [15] Yang DF, Qiu WH, Zhu HF, et al. CTLA4-Ig-modified dendritic cells inhibit lymphocyte-mediated alloimmune responses and prolong the islet graft survival in mice[J]. Transpl Immunol,2008,19(3/4):197-201. http://cn.bing.com/academic/profile?id=2073000529&encoded=0&v=paper_preview&mkt=zh-cn
    [16] Kim SH, Kim S, Oligino TJ,et al. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL[J].Mol Ther,2002,6(5):584-590. doi: 10.1016/S1525-0016(02)90712-4
    [17] Liu Z, Xu X, Hsu HC, et al. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis[J]. J Clin Invest,2003,112(9):1332-1341. doi: 10.1172/JCI200319209
    [18] Toscano MG, Delgado M, Kong W, et al. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs[J]. Mol Ther,2010,18(5):1035-1045. doi: 10.1038/mt.2009.293
    [19] Kushwah R, Oliver JR, Duan R, et al. Induction of immunological tolerance to adenoviral vectors by using a novel dendritic cell-based strategy[J]. J Virol,2012,86(7):3422-3435. doi: 10.1128/JVI.06172-11
    [20] Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based immunotherapy for autoimmunity[J]. Int Rev Immunol,2010,29(2):156-183. doi: 10.3109/08830180903281193
    [21] Beriou G, Moreau A, Cuturi MC. Tolerogenic dendritic cells: applications for solid organ transplantation[J]. Curr Opin Organ Transplant,2012,17(1):42-47. doi: 10.1097/MOT.0b013e32834ee662
    [22] Taner T, Hackstein H, Wang Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival[J]. Am J Transplant,2005,5(2):228-236. doi: 10.1046/j.1600-6143.2004.00673.x
    [23] Horibe EK, Sacks J, Unadkat J, et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion[J]. Transpl Immunol,2008,18(4):307-318. doi: 10.1016/j.trim.2007.10.007
    [24] Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits IL-4:induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo[J]. Blood,2003,101(11):4457-4463. doi: 10.1182/blood-2002-11-3370
    [25] Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance[J]. J Immunol,2007,178(11):7018-7031. doi: 10.4049/jimmunol.178.11.7018
    [26] Eun SC, Baek RM, Park CG. Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506[J]. Transplant Proc,2013,45(5):1792-1796. doi: 10.1016/j.transproceed.2013.01.021
    [27] Zahorchak AF, Raimondi G, Thomson AW. Rhesus monkey immature monocyte-derived dendritic cells generate alloantigen-specific regulatory T cells from circulating CD4+ CD127-/lo T cells[J]. Transplantation,2009,88(9):1057-1064. doi: 10.1097/TP.0b013e3181ba6b1f
    [28] Chorny A, Gonzalez-Rey E, Fernandez-Martin A, et al. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response[J]. Blood,2006,107(9):3787-3794. doi: 10.1182/blood-2005-11-4495
    [29] Martin E, Capini C, Duggan E, et al. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB[J]. Arthritis Rheum,2007,56(7):2255-2266. doi: 10.1002/(ISSN)1529-0131
    [30] Orange DE, Blachere NE, Fak J, et al. Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo[J]. Elife,2013,2:e00105. http://cn.bing.com/academic/profile?id=2145591110&encoded=0&v=paper_preview&mkt=zh-cn
    [31] Stoop JN, Harry RA, von Delwig A, et al. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses[J]. Arthritis Rheum,2010,62(12):3656-3665. doi: 10.1002/art.27756
    [32] Cheatem D, Ganesh BB, Gangi E, et al. Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+ CD25+ regulatory T cell function[J]. Clin Immunol,2009,131(2):260-270. doi: 10.1016/j.clim.2008.12.001
    [33] Tai N, Yasuda H, Xiang Y, et al. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice[J]. Clin Immunol,2011,139(3):336-349. doi: 10.1016/j.clim.2011.03.003
    [34] Bellinghausen I, Reuter S, Martin H, et al. Enhanced production of CCL18 by tolerogenic dendritic cells is associated with inhibition of allergic airway reactivity[J]. J Allergy Clin Immunol,2012,130(6):1384-1393. doi: 10.1016/j.jaci.2012.08.039
    [35] Hill M, Thebault P, Segovia M, et al. Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and epstein-barr virus-induced gene 3[J]. Am J Transplant,2011,11(10):2036-2045. doi: 10.1111/ajt.2011.11.issue-10
    [36] Pujol-Autonell I, Ampudia RM, Monge P, et al. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice[J]. ISRN Endocrinol,2013:346987. http://cn.bing.com/academic/profile?id=1983086869&encoded=0&v=paper_preview&mkt=zh-cn
    [37] Marin-Gallen S, Clemente-Casares X, Planas R, et al. Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes[J]. Clin Exp Immunol,2010,160(2):207-214. http://cn.bing.com/academic/profile?id=1524269662&encoded=0&v=paper_preview&mkt=zh-cn
    [38] Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells[J]. J Exp Med,2001,193(2):233-238. doi: 10.1084/jem.193.2.233
    [39] Stoop JN, Robinson JH, Hilkens CM. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models?[J]. Ann Rheum Dis,2011,70(9):1526-1533. doi: 10.1136/ard.2011.151654
    [40] Hilkens CM, Isaacs JD. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?[J]. Clin Exp Immunol,2013,172(2):148-157. doi: 10.1111/cei.2013.172.issue-2
    [41] Macedo C, Turquist H, Metes D, et al. Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation[J]. Transplant Res,2012,1(1):16. doi: 10.1186/2047-1440-1-16
    [42] Moreau A, Varey E, Bouchet-Delbos L, et al. Cell therapy using tolerogenic dendritic cells in transplantation[J]. Transplant Res,2012,1(1):13. doi: 10.1186/2047-1440-1-13
    [43] Beriou G, Moreau A, Cuturi MC. Tolerogenic dendritic cells: applications for solid organ transplantation[J]. Curr Opin Organ Transplant,2012,17(1):42-47. doi: 10.1097/MOT.0b013e32834ee662
    [44] Moreau A, Varey E, Bériou G, et al. Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials[J]. Front Immunol,2012,3:218. http://cn.bing.com/academic/profile?id=2122806193&encoded=0&v=paper_preview&mkt=zh-cn
    [45] Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation[J]. Semin Immunol,2011,23(4):252-263. doi: 10.1016/j.smim.2011.06.007
    [46] Giannoukakis N, Phillips B, Finegold D, et al. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients[J]. Diabetes Care,2011,34(9):2026-2032. doi: 10.2337/dc11-0472
    [47] Harry RA, Anderson AE, Isaacs JD, et al. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis[J]. Ann Rheum Dis,2010,69(11):2042-2050. doi: 10.1136/ard.2009.126383
  • 加载中
计量
  • 文章访问数:  76
  • HTML全文浏览量:  231
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-09-15
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2014-01-15

目录

    /

    返回文章
    返回